Efficacy, Effect on Mood Symptoms, and Safety of Deep Brain Stimulation in Refractory Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article.

Overview

First-line treatments for OCD include selective serotonin reuptake inhibitors and cognitive-behavioral therapy. But what do you do when patients do not respond to these or second-line strategies? In this journal CME activity, explore the option of deep brain stimulation.


Read the whole article at psychiatrist.com here:
Efficacy, Effect on Mood Symptoms, and Safety of Deep Brain Stimulation in Refractory Obsessive-Compulsive Disorder:  A Systematic Review and Meta-Analysis

© Copyright 2020 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Consider the use of deep brain stimulation for patients with severe, refractory obsessive-compulsive disorder and depressive symptoms

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
05/26/2020
Activity expires: 
06/30/2022
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

To obtain credit, read the article, correctly answer the questions in the Posttest, and complete the Evaluation. A $10 processing fee will apply.

CME Objective

After studying this article, you should be able to:

  • Consider the use of deep brain stimulation for patients with severe, refractory obsessive-compulsive disorder and depressive symptoms

Statement of Need and Purpose

Clinicians need education about the latest evidence on treatment strategies for refractory OCD and how treatments such as DBS might also improve comorbid depression. Many patients with OCD do not reach remission with first-line treatment or subsequent therapies. Surgical options such as DBS, which has been associated with symptomatic improvement in not only OCD symptoms but also mood symptoms, may be considered when other treatments are deemed ineffective.

Release, Expiration, and Review Dates

This educational activity was published in May 2020 and is eligible for AMA PRA Category 1 Credit™ through June 30, 2022. The latest review of this material was May 2020.

Disclosure of Off-Label usage

The authors have determined that, to the best of their knowledge, use of deep brain stimulation devices outside of US Food and Drug Administration–approved labeling may have been performed in the studies evaluated in this meta-analysis. Please check indications on labeling provided by manufacturers.

Funding/Support

The authors have no support or funding to report.

Faculty Affiliation


Filipe Peste Martinho, MD*
Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
 

Gonçalo Silva Duarte, MD
Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
 


Frederico Simões do Couto, MD, PhD
Psychiatry and Psychology Department, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal


*Corresponding author: Filipe Peste Martinho, MD, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal (filipepestemartinho@gmail.com).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

Drs MartinhoDuarte, and Simões do Couto have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

 

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.